Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3791-3799

  Das, Jharna R ^a   Fryar Tita, Elizabeth B ^c   Zhou, Yanfei ^b   Green, Sidney ^a   Southerland, William M ^a   Bowen, Donnell ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HOWARD UNIVERSITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

5 fluorouracil; Estrogen negative breast cancer cell lines; Methotrexate

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW CELLS; BONE MARROW DISEASES; BREAST NEOPLASMS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUOROURACIL; HUMANS; METHOTREXATE; RECEPTORS, ESTROGEN;

EID: 37549047943     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Perera NM and Gui GP: Multi-ethnic differences in breast cancer: current concepts and future directions. Int J Cancer 106: 463-467, 2003.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
4. American Cancer Society. Cancer facts and figures-2001. Atlanta: American Cancer Society, 2001.
5. Phillips J and Smith ED: Breast cancer control and African American women: a review. Cancer Invest 19: 273-280, 2001.
6. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, Muss H, Hunter CP, Redmond C, Sobhan M, Coates R, Reynolds P, Herman AA and Edwards EK: Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 3: 127-135, 1994.
7. Early Breast Cancer Trialists Collaborative Groups: Effect of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an over view of randomized trials. Lancet 356: 1687-1717, 2005.
8. Jordan VC and Gradishar WJ: Molecular mechanisms and future uses of antiestrogens. Mol Aspects Med 18: 167-247, 1997.
9. Labrie F, Labrie C, Belanger A, Simard J, Gauthier S, Luu-The V, Merand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L and Veilleux R: EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 69: 51-84, 1999.
10. Filardo EJ: Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80: 231-238, 2002.
11. Filardo EJ, Quinn JA, Bland KI and Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14: 1649-1660, 2000.
12. Bowen D, Johnson DH, Southerland WM, Hughes DE and Hawkins M: 5-Fluorouracil simultaneously maintains methotrexate antineoplastic activity in human breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res 19: 985-988, 1999.
13. Bowen D, Southerland WM, Johnson DH, Hawkins M Jr and Hughes DE: Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells. Cancer Detect Prev 24: 452-458, 2000.
14. White RM: 5-Fluorouracil modulates the toxicity of high dose methotrexate. J Clin Pharmacol 35: 1156-1165, 1995.
15. Das JR, Fryar EB, Epie NN, Southerland WM and Bowen D: Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res 26: 1877-1884, 2006.
16. Jolivet J, Schilsky RL, Bailey BD, Drake JC and Chabner BA: Synthesis retention, and biological activity of methotrexate polyglutamates in cultured human bone marrow. J Clin Invest 70: 351-360, 1982.
17. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC and Jolivet J: Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76: 907-912, 1985.
18. Koizumi S, Curt GA, Fine RL, Griffin JD and Chabner BA: Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 75: 1008-1014, 1985.
19. Matthews RG and Baugh CM: Interactions of pig liver methylenetetrahydrofolate reductase with methylenetetrahydropteroylpolyglutamate substrates and with dihydropteroylpolyglutamate inhibitors. Biochemistry 19: 2040-2045, 1980.